| Location: | District of Columbia |
|---|---|
| Posted: | Oct 9, 2025 |
| Due: | Dec 19, 2025 |
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
| Type of Government: | Federal |
| Category: |
|
| Solicitation No: | ARPA-H-SOL-25-122 |
| Publication URL: | To access bid details, please log in. |
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
Amendment 1: Added the Frequently Asked Questions (FAQ) to the list of attachments.
The Advanced Research Projects Agency for Health (ARPA-H) Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) program envisions a future where patients can opt for one-time therapeutic interventions designed to slow, reverse, or cure disease, harnessing revolutionary technologies and a rapidly evolving understanding of the genetic underpinnings of the biological processes that lead to disease.
Interested parties are invited to review the attached THRIVE Innovative Solutions Opening (ISO) ARPA-H -SOL-25-122.
For detailed information regarding Proposers' Day review Special Notice (SN) ARPA-H-SN-25-131.
Solution summaries are due October 31, 2025, 11:59 PM ET.
For more information about THRIVE, please visit:https://arpa-h.gov/explore-funding/programs/thrive
| Sep 25, 2025 | [Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE) |
| Oct 17, 2025 | [Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE) |
| Oct 27, 2025 | [Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE) |
| Nov 15, 2025 | [Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE) |
| Dec 2, 2025 | [Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE) |
| Dec 15, 2025 | [Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE) |
| Jan 9, 2026 | [Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE) |

With GovernmentContracts, you can:
Follow Q701--Radiation Oncology Quality Surveillance (VHA-ROQS) Program Active Contract Opportunity Notice ID 36C24526Q0635
VETERANS AFFAIRS, DEPARTMENT OF
Bid Due: 8/31/2026
Follow Pure Storage Flash Array Systems (Brand Name Only) Active Contract Opportunity Notice
DEPT OF DEFENSE
Bid Due: 7/30/2026
Follow DBA Insurance Rate Agreement Active Contract Opportunity Notice ID 19AQMM26Q0155 Related Notice
STATE, DEPARTMENT OF
Bid Due: 7/31/2026
Follow Next Generation (NextGen) Passport Personalization Printers Support Active Contract Opportunity Notice ID
STATE, DEPARTMENT OF
Bid Due: 8/17/2026